Dying for Drugs: How CAFTA Will Undermine Access to Essential Medicines

By Weissman, Robert | Multinational Monitor, April 2004 | Go to article overview
Save to active project

Dying for Drugs: How CAFTA Will Undermine Access to Essential Medicines

Weissman, Robert, Multinational Monitor

THERE ARE ROUGHLY 44 MILLION PEOPLE in the Central American countries of Guatemala, Honduras, Nicaragua, El Salvador and Costa Rica, plus the Dominican Republic. Their per capita income ranges from $370 a year in Nicaragua to $1,750 in Guatemala to more than $4,000 in Costa Rica.

The corporate members of the U.S. Pharmaceuticals Research and Manufacturers of America (PhRMA) look at Central America and see a market to conquer.

U.S. drug companies presently export about $50 million worth of drugs a year to the Central America and the Dominican Republic.

With adoption of the U.S.-Central America Free Trade Agreement (CAFTA), which includes the five Central American countries, plus a U.S.-Dominican Republic deal that is being "docked" on to CAFTA, the drug companies think they can make more.

According to Renard Aron, assistant vice president for Latin America and Canada at PhRMA, that's due in part to the tariff provisions of the agreement, which would bring down tariffs on imported pharmaceuticals--and enable the brand-name drug companies to raise their prices commensurately.

But most important to PhRMA is the intellectual property provisions of CAFTA.

"A higher level of intellectual property protection ... is important to the research-based pharmaceutical industry," Aron told the U.S. International Trade Commission at an April hearing.

"We look forward to every government in the region to implement the Agreement in a transparent and timely fashion, ensuring the applicability of strong and enforceable rights established by the Agreement."

Things look different to public health groups.

They say PhRMA should leave the poor Central American countries alone, without demanding the imposition of heightened intellectual property rules to extend and expand brand-name drug company monopolies.

CAFTA's patent and other intellectual property, rules will, they say, delay generic competition and artificially raise the price of drugs, with the result that Central Americans will be denied medicines they need to treat illnesses, including life-threatening diseases.

"CAFTA negotiators have given in to U.S. pressure and failed their people by agreeing to measures that place profits above people's lives," says Rachel Cohen, U.S. director of the Campaign for Access to Essential Medicines of the international medical humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF).


It is beyond dispute that the introduction of generic competition lowers price dramatically and enables broadened access to needed medicine. The very purpose of patent monopolies is to enable patent holders to collect supracompetitive profits, as a reward and incentive for innovation. There is now several decades experience in the United States illustrating the price reductions from generic competition.

And, several years into the international campaign for access to essential medicines, generic competition has brought down the price of lifesaving antiretrovirals used to treat people with HIV/MDS by more than 98 percent. Generic firms from India now offer triple-drug MDS cocktails for as little as $140 a year. A few years ago, the brand-name companies sold the same products for $10,000 a year or more in poor countries. Prodded by generic competition and activist campaigns, the brand-name companies have dropped their prices significantly, but the lowest brand-name prices for MDS drugs remain roughly four times the cost of the cheapest generic option. (Both the generics and brand-name companies decline to make their biggest discount prices available in Central America, which is not as poor as sub-Saharan Africa.)

Under the rules of the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (WTO's TRIPS), countries are required to provide 20-year patent protections for all products, including pharmaceuticals.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Dying for Drugs: How CAFTA Will Undermine Access to Essential Medicines


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?